*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2026 | NLRP3 autophagic degradation disruption in melanocytes contributes to vitiligo development Cell death and differentiation · preclinical | PMID 40935835 |
| 2025 | Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway Tissue & cell · preclinical | PMID 40073467 |
| 2024 | KPV and RAPA Self-Assembled into Carrier-Free Nanodrugs for Vascular Calcification Therapy Advanced healthcare materials · preclinical | PMID 39252648 |
| 2022 | A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon Acta biomaterialia · preclinical | PMID 35245681 |
| 2017 | Peptide Receptor-Targeted Fluorescent Probe: Visualization and Discrimination between Chronic and Acute Ulcerative Colitis ACS applied materials & interfaces · preclinical | PMID 28349696 |
| 2012 | Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists International journal of physiology, pathophysiology and pharmacology · preclinical | PMID 22837805 |
| 2008 | PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation Gastroenterology · preclinical | PMID 18061177 |
| 2004 | alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells The Journal of investigative dermatology · preclinical | PMID 15102092 |
| 2003 | Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides The Journal of pharmacology and experimental therapeutics · preclinical | PMID 12750433 |
| 2003 | New insights into the functions of alpha-MSH and related peptides in the immune system Annals of the New York Academy of Sciences · preclinical | PMID 12851308 |
| 2000 | The neuropeptide alpha-MSH in host defense Annals of the New York Academy of Sciences · preclinical | PMID 11268348 |
| 2000 | The neuroimmunomodulatory peptide alpha-MSH Annals of the New York Academy of Sciences · preclinical | PMID 11268347 |
KPV (KPV (Lys-Pro-Val; alpha-MSH C-terminal tripeptide)). C-terminal tripeptide of alpha-melanocyte-stimulating hormone. Anti-inflammatory via NF-kB pathway modulation; studied in colitis/gut-inflammation models without the pigmentary effects of full alpha-MSH.
Commonly discussed uses: gut inflammation research, anti-inflammatory/skin (anecdotal). The evidence base is largely preclinical (animal/in-vitro); published randomised human clinical trials are lacking or absent. Note: most uses are not approved indications.
Mechanism: C-terminal tripeptide of alpha-melanocyte-stimulating hormone. Anti-inflammatory via NF-kB pathway modulation; studied in colitis/gut-inflammation models without the pigmentary effects of full alpha-MSH.
Reported considerations: limited human safety data, anecdotal: well tolerated. The evidence base is largely preclinical (animal/in-vitro); published randomised human clinical trials are lacking or absent. Research peptide; preclinical evidence only. Not approved. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low 200mcg/day, typical 250-500mcg/day, high 500mcg/day. Administration: oral, subcutaneous, topical. Half-life: short.
Australian status: Not ARTG-registered; research. Research peptide; preclinical evidence only. Not approved. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: 2ml BAC water per 5-10mg vial; storage: refrigerated.
Commonly discussed combinations (anecdotal for unapproved compounds): KPV + BPC-157 (gut protocols, anecdotal). Stacking increases interaction/safety uncertainty.